Tools
Stock profile

JOHNSON & JOHNSON (JNJ)

JNJ · Latest close $272.70 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$272.70
As of Nov 18, 2026
Tracked funds holding
26 of 149
2026 Q2 13F filings
Opened / added
3 / 4
vs previous quarter
Trimmed / exited
13
vs previous quarter

JOHNSON & JOHNSON (JNJ) is held by 26 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds opening new positions, 4 funds adding, and 13 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $12.9M sold). 1 member of Congress reported 2 purchases vs 6 sales. Latest close $272.70 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 12, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-12.9M
Congress
2 buys vs 6 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

ACR Alpine Capital Research · Independent Franchise Partners · Guinness Asset Management — 26 tracked funds hold JNJ. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 3 sales ($12.9M). Insider trading 1 member of Congress reported buying (2 purchases vs 6 sales). Latest buy: Sep 8, 2026. Politician trading

Often held alongside

GILEAD SCIENCES, INC. (GILD) · ILLINOIS TOOL WORKS INC (ITW) · 3M CO (MMM) · FACTSET RESEARCH SYSTEMS INC (FDS) · GENERAL MILLS INC (GIS) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
ACR Alpine Capital Research7.74%2,146,488TRIMMED (-0.5%) Q3 filed Nov 2
Independent Franchise Partners5.07%3,043,186ADDED (+2.4%) Q3 filed Nov 13
Guinness Asset Management4.43%1,036,908TRIMMED (-5.2%) Q3 filed Nov 5
Yacktman Asset Management3.96%1,259,977ADDED (+0.8%) Q3 filed Nov 2
Tweedy Browne3.88%201,644TRIMMED (-8.1%) Q3 filed Nov 4
PineStone Asset Management2.72%1,733,844TRIMMED (-3.1%) Q3 filed Oct 16
DJE Kapital2.53%510,682TRIMMED (-32.0%) Q3 filed Nov 12
Bristol (John W. Bristol & Co.)1.31%348,528TRIMMED (-1.0%) Q3 filed Nov 13
Markel Group1.18%610,800HELD Q3 filed Oct 30
Axiom Investors1.08%491,072NEW Q3 filed Nov 12

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +9.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

285.75136.312024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

342016Q3: 33 funds2016Q4: 34 funds2017Q1: 31 funds2017Q2: 32 funds2017Q3: 31 funds2017Q4: 34 funds2018Q1: 32 funds2018Q2: 31 funds2018Q3: 29 funds2018Q4: 28 funds2019Q1: 29 funds2019Q2: 28 funds2019Q3: 28 funds2019Q4: 27 funds2020Q1: 27 funds2020Q2: 28 funds2020Q3: 28 funds2020Q4: 29 funds2021Q1: 29 funds2021Q2: 31 funds2021Q3: 30 funds2021Q4: 28 funds2022Q1: 27 funds2022Q2: 29 funds2022Q3: 30 funds2022Q4: 30 funds2023Q1: 27 funds2023Q2: 27 funds2023Q3: 25 funds2023Q4: 23 funds2024Q1: 21 funds2024Q2: 22 funds2024Q3: 22 funds2024Q4: 22 funds2025Q1: 21 funds2025Q2: 23 funds2025Q3: 23 funds2025Q4: 24 funds2026Q1: 24 funds2026Q2: 26 funds2016Q32026Q2

Tracked funds holding this stock, by quarter (2016Q3–2026Q2, 40 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding4,687 of 8,857 filers
Long-only filers among them4,672
Change vs 2026 Q1+101 net · 2,077 entered · 1,976 exited
Shares reported, all filers1,774,772,948
Reported value, all filers$445.6B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$94.2B
Net income · FY2025$26.8B
Total assets · FY2025$199.2B
Shares outstanding2,407,310,266
Market cap (at latest close)$656.5B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 15, 2026.

Short interest

Shares short · Oct 15, 202616,766,729
Share of shares outstanding0.70%
Days to cover1.97

Shares short at recent settlements — Jul 31, 2026: 25.4M · Aug 14, 2026: 21.6M · Aug 31, 2026: 21.7M · Sep 15, 2026: 21.2M · Sep 30, 2026: 22.1M · Oct 15, 2026: 16.8M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 15, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 2026157
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 2026<0.1%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 129 · Oct 14, 2026: 157.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 15, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 3 sales by 2 insiders ($12.9M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 12, 2026Forminard ElizabethEVP, Chief Legal OfficerSell13,072$284.39$3.7MSEC filing
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechSell11,070$274.74$3.0MSEC filing
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechSell22,527$274.74$6.2MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 2, 2026Schmid TimothyOfficer33,597$9.2MSep 2, 2026SEC filing
Aug 17, 2026Taubert Jennifer LOfficer15,000$4.0MAug 17, 2026SEC filing
Aug 13, 2026Duato JoaquinOfficer, Director123,291$32.2MAug 13, 2026SEC filing
Aug 6, 2026Forminard ElizabethOfficer15,918$4.1MAug 6, 2026SEC filing
Aug 5, 2026Joaquin DuatoCEO, Chariman48,480$12.4MAug 5, 2026SEC filing
Jul 20, 2026Broadhurst VanessaOfficer23,054$5.8MJul 20, 2026SEC filing
Jun 11, 2026Wengel Kathryn EOfficer10,000$2.4MJun 11, 2026SEC filing
Feb 27, 2026Decker Robert JOfficer4,075$1.0MFeb 27, 2026SEC filing
Feb 20, 2026Schmid TimothyOfficer1,322$324.8KFeb 20, 2026SEC filing
Feb 18, 2026Schmid TimothyOfficer22,623$5.5MFeb 18, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 1, 2026Vanguard Capital ManagementSC 13G180,631,2287.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 5, 2026The Vanguard GroupSC 13G/A243,455,13510.1%Jan 30, 2026SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (2 purchases vs 6 sales). Bought by Democrats. Latest buy: Sep 8, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Kean, Thomas H.HouseR04Sep 30, 2026$1,001 - $15,000
Doggett, LloydHouseD20Sep 8, 2026$1,001 - $15,000
Boozman, JohnSenateR01Aug 20, 2026$1,001 - 15,000
McCormick, Richard DeanHouseR01Jul 30, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

Member who traded this stockSits on
Kean, Thomas H.House Committee on Energy and Commerce

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 3,158 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (1,058), Taxation/Internal Revenue Code (637), Budget/Appropriations (601).

Federal contracts: $552.8M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$118.2M
FY2022$113.1M
FY2023$125.8M
FY2024$89.9M
FY2025$60.6M
FY2026$45.2M

Largest awards collected

Award IDAgencyAmountStart
VA25816F0553Department of Veterans Affairs$9.3MFeb 18, 2016
VA25817J0061Department of Veterans Affairs$6.8MOct 6, 2016
VA24917J3516Department of Veterans Affairs$4.8MJul 1, 2017
HHSI247201700086GDepartment of Health and Human Services$3.3MMay 22, 2017
FA480015F0007Department of Defense$2.8MDec 2, 2014

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Financial Screens

· Buffett — Companies with high ROE sustained for more than a decade

· Dividend Growth — Dividends raised for more than 10 years

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· 52-Week High — Recently printed a new 52-week high

Key figures

· Buffett — Latest ROE: 32.9% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 24.8% · Latest net income: $26.8B

· Dividend Growth — Dividend per share: 5.14 · Dividend yield: 1.9% · Straight dividend years: 16 · 10-yr dividend growth: 86.2%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.10 · Operating cash flow: $24.5B · Net income: $26.8B

· Earnings Stability — Earnings variation (CV): 0.48 · Loss years (of 10): 0 · Latest net income: $26.8B

· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 6 · Latest buy: Sep 8, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 40 of the last 40 quarterly lists; latest 2026 Q2, ranked #18 of 50.

· Politician BEST — appeared in 16 of the last 20 quarterly lists; latest 2025 Q4, ranked #25 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1275.0%+4.4%+1.8%+2.6%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold JNJ — ranked by lift, the co-holding pattern described in Methodology: GILEAD SCIENCES, INC. (GILD) · ILLINOIS TOOL WORKS INC (ITW) · 3M CO (MMM) · FACTSET RESEARCH SYSTEMS INC (FDS) · GENERAL MILLS INC (GIS) · NORTHERN TRUST CORP (NTRS) · RIO TINTO PLC (RIO) · ROCKWELL AUTOMATION, INC (ROK).

Filings audit: every filing lens on JOHNSON & JOHNSON (JNJ), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Oct 13, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and ExhibitsSEC filing
Jul 29, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

GILEAD SCIENCES, INC. (GILD) · Filings audit: every filing lens on JOHNSON & JOHNSON (JNJ), scored · Practice timing on JNJ

One email a week: the week’s new filings and research. Subscribe free

← JLL  ·  JOBY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.